# Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction With Type 2 Diabetes Mellitus Study

Study · id `cardio:ct-nct02449330` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02449330](<https://clinicaltrials.gov/study/NCT02449330>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02449330

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 936 participants.

## Technical summary

Registry record NCT02449330. Randomized; single masking; primary purpose treatment. Start 2015-06 (registry gives no type); primary completion 2020-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 936 participants (planned count; ClinicalTrials.gov record NCT02449330, source copy `cardio:ctgov-nct02449330-2018-08-22`, retrieved 2026-10-26)
- Start date: 2015-06 (registry gives no type) (ClinicalTrials.gov record NCT02449330, source copy `cardio:ctgov-nct02449330-2018-08-22`, retrieved 2026-10-26)
- Primary completion: 2020-06 (anticipated) (ClinicalTrials.gov record NCT02449330, source copy `cardio:ctgov-nct02449330-2018-08-22`, retrieved 2026-10-26)
- Completion: 2023-06 (anticipated) (ClinicalTrials.gov record NCT02449330, source copy `cardio:ctgov-nct02449330-2018-08-22`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT02449330, source copy `cardio:ctgov-nct02449330-2018-08-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02449330-2018-08-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Teneligliptin on the Progressive Left Ventricular Diastolic Dysfunction With Type 2 Diabetes Mellitus Study
- Acronym: TOPLEVEL
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Teneligliptin
- Lead sponsor: National Cerebral and Cardiovascular Center, Japan
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: National Cerebral and Cardiovascular Center, Japan (`cardio:org-national-cerebral-and-cardiovascular-center-japan`)

## Provenance

Content hash: 302ca010630cec5361d77b53c950c1b7b08e4f0f8f8db71105f4c99fba3ffb4f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
